Product Details
| Product Name:
ONX-0914 |
CAS No.:
960374-59-8 |
| Purity:
98.47% |
Supply Ability:
10g |
| Release date:
2025/07/31 |
Product Introduction
Bioactivity
| Name | ONX-0914 |
| Description | ONX-0914 (PR-957) is a potent and highly specific immunoproteasome inhibitor with minimal cross-reactivity to the constitutive proteasome. |
| Kinase Assay | 20 ng of purified human DDK is pre-incubated with increasing concentrations of each DDK inhibitor for 5 min. Then 10 μCi (γ)-32P ATP and 1.5 μM cold ATP are added in a buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, and 1 mM DTT and incubated for 30 min at 30°C. The proteins are denatured in 1X Laemmli buffer at 100°C followed by SDS-PAGE and autoradiography on HyBlot CL film. Auto-phosphorylation of DDK is used as an indicator of its kinase activity. 32P-labeled bands are quantified using ImageJ and the IC50 values are calculated using GraphPad. |
| In vitro | Selective inhibition of LMP7 by PR-957 blocked production of interleukin-23 (IL-23) by activated monocytes and interferon-gamma and IL-2 by T cells. |
| In vivo | In mouse models of rheumatoid arthritis and lupus, the maximum tolerated dose (MTD) of ONX-0914 in mice to be 30 mg/kg body weight. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (86.11 mM), Sonication is recommended.
|
| Keywords | Proteasome | PR957 | PR 957 | ONX-0914 | Inhibitor | inhibit | Human immunodeficiency virus | HIVProtease | HIV Protease | HIV | Bacterial |
| Inhibitors Related | Neomycin sulfate | Stavudine | Emtricitabine | Ampicillin sodium | Doxycycline (hyclate) | Kanamycin sulfate | Sulfamethoxazole sodium | Lamivudine | Doxycycline | Isoeugenol | Dimethyl sulfoxide | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Bioactive Compound Library | Ubiquitination Compound Library | Hematonosis Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Bacterial Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | Anti-Infection Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2939933-03-4
$335.00 / 1mg
-
CAS:79551-86-3
$2450.00 / 5mg
-
CAS:210891-04-6
$988.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$0.00/1KG |
VIP4Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-10-13 |
United States